Format

Send to

Choose Destination
Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10.

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Author information

1
Department of Radiation Oncology, Cantonal Hospital St. Gallen, Switzerland. Electronic address: cedric.panje@kssg.ch.
2
Department of Gynecology, University Hospital Zurich, Switzerland.
3
Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland; Institute of Pharmaceutical Medicine, University of Basel, Switzerland.
4
Institute of Pharmaceutical Medicine, University of Basel, Switzerland.
5
Medical Oncology, Department of Internal Medicine, Cantonal Hospital Lucerne, Switzerland.
6
Department of Medical Oncology, Cantonal Hospital St. Gallen, Switzerland.
7
Department of Radiation Oncology, University of Bern, Switzerland.
8
Department of Radiation Oncology, Cantonal Hospital St. Gallen, Switzerland; Department of Radiation Oncology, University of Bern, Switzerland.

Abstract

BACKGROUND:

Novel systemic therapies have improved the prognosis of metastatic non-small cell lung cancer (NSCLC), but costs of some of these drugs are a matter of ongoing debate. More recently, local therapies (LT) such as radiotherapy and surgery have been suggested as additional treatment in oligometastatic NSCLC demonstrating an improved progression-free survival (PFS) in a phase II trial compared to maintenance chemotherapy (MC) alone. The aim of this analysis was to assess the cost-effectiveness of local therapies in oligometastatic NSCLC.

METHODS:

We constructed a Markov model comparing the cost-effectiveness of LT versus MC for oligometastatic NSCLC from the Swiss healthcare payer's perspective. Treatment specifications and PFS were based on the phase II trial (NCT01725165). Overall survival (OS) was inferred from a recent phase III trial. Utilities were taken from published data. Primary outcome was the incremental cost-effectiveness-ratio (ICER, costs in Swiss Francs (CHF) per quality-adjusted life-year (QALY) gained).

RESULTS:

PFS in the model was 3.8 months for MC and 11.4 months for LT (compared to 3.9 months and 11.9 months in the trial). OS in the model was 15.5 months in both arms. LT was cost-effective with a gain of 0.24 QALYs at an additional cost of CHF 9641, resulting in an ICER of CHF 40,972/QALY gained. Probabilistic sensitivity analyses demonstrated that LT was dominant or cost-effective at a willingness-to-pay threshold of CHF 100,000 per QALY in 61.7% of the simulations.

CONCLUSIONS:

LT may be cost-effective for selected patients with oligometastatic NSCLC responding to first-line systemic therapy.

KEYWORDS:

Cost-effectiveness; Incremental cost-effectiveness ratio; Lung cancer; Oligometastatic; Quality-adjusted life year

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center